Skip to main content
Erschienen in: Strahlentherapie und Onkologie 7/2014

01.07.2014 | Original article

Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases

verfasst von: A. S. Berghoff, A. Ilhan-Mutlu, A. Wöhrer, M. Hackl, G. Widhalm, J. A. Hainfellner, K. Dieckmann, T. Melchardt, B. Dome, H. Heinzl, P. Birner, MD, M. Preusser

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Survival upon diagnosis of brain metastases (BM) in patients with non-small cell lung cancer (NSCLC) is highly variable and established prognostic scores do not include tissue-based parameters.

Methods

Patients who underwent neurosurgical resection as first-line therapy for newly diagnosed NSCLC BM were included. Microvascular density (MVD), Ki67 tumor cell proliferation index and hypoxia-inducible factor 1 alpha (HIF-1 alpha) index were determined by immunohistochemistry.

Results

NSCLC BM specimens from 230 patients (151 male, 79 female; median age 56 years; 199 nonsquamous histology) and 53/230 (23.0 %) matched primary tumor samples were available. Adjuvant whole-brain radiation therapy (WBRT) was given to 153/230 (66.5 %) patients after neurosurgical resection. MVD and HIF-1 alpha indices were significantly higher in BM than in matched primary tumors. In patients treated with adjuvant WBRT, low BM HIF-1 alpha expression was associated with favorable overall survival (OS), while among patients not treated with adjuvant WBRT, BM HIF-1 alpha expression did not correlate with OS. Low diagnosis-specific graded prognostic assessment score (DS-GPA), low Ki67 index, high MVD, low HIF-1 alpha index and administration of adjuvant WBRT were independently associated with favorable OS. Incorporation of tissue-based parameters into the commonly used DS-GPA allowed refined discrimination of prognostic subgroups.

Conclusion

Ki67 index, MVD and HIF-1 alpha index have promising prognostic value in BM and should be validated in further studies.
Literatur
1.
Zurück zum Zitat Yamanaka R (2009) Medical management of brain metastases from lung cancer (Review). Oncol Rep 22:1269–1276PubMedCrossRef Yamanaka R (2009) Medical management of brain metastases from lung cancer (Review). Oncol Rep 22:1269–1276PubMedCrossRef
2.
Zurück zum Zitat Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425PubMedCentralPubMedCrossRef Sperduto PW et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRef Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRef
4.
Zurück zum Zitat Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514CrossRef Sperduto PW et al (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510–514CrossRef
5.
Zurück zum Zitat Rades D et al (2013) A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 189:777–781PubMedCrossRef Rades D et al (2013) A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 189:777–781PubMedCrossRef
6.
Zurück zum Zitat Huang C et al (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92:1231–1239PubMedCentralPubMedCrossRef Huang C et al (2005) Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92:1231–1239PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Trivella M et al (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8:488–499PubMedCrossRef Trivella M et al (2007) Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 8:488–499PubMedCrossRef
8.
Zurück zum Zitat Yohena T et al (2009) Upregulation of hypoxia-inducible factor-1 alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol 4:284–290PubMedCrossRef Yohena T et al (2009) Upregulation of hypoxia-inducible factor-1 alpha mRNA and its clinical significance in non-small cell lung cancer. J Thorac Oncol 4:284–290PubMedCrossRef
9.
Zurück zum Zitat Park S et al (2011) Prognostic implications of hypoxia-inducible factor-1 alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:100–107PubMedCrossRef Park S et al (2011) Prognostic implications of hypoxia-inducible factor-1 alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 72:100–107PubMedCrossRef
10.
Zurück zum Zitat Kim SJ et al (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335PubMedCrossRef Kim SJ et al (2005) Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335PubMedCrossRef
11.
Zurück zum Zitat Wohrer A et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401–411PubMedCrossRef Wohrer A et al (2009) The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95:401–411PubMedCrossRef
12.
Zurück zum Zitat Preusser M et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47PubMedCrossRef Preusser M et al (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47PubMedCrossRef
13.
Zurück zum Zitat Birner P et al (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143PubMedCrossRef Birner P et al (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143PubMedCrossRef
14.
Zurück zum Zitat Zhong H et al (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed Zhong H et al (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 59:5830–5835PubMed
15.
Zurück zum Zitat Cappuzzo F et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRef Cappuzzo F et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655PubMedCrossRef
16.
Zurück zum Zitat Hirsch FR et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807PubMedCrossRef Hirsch FR et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798–3807PubMedCrossRef
17.
Zurück zum Zitat Spanberger T et al (2013) Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis 30:357–368PubMedCrossRef Spanberger T et al (2013) Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis 30:357–368PubMedCrossRef
18.
Zurück zum Zitat Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180PubMedCrossRef Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180PubMedCrossRef
19.
Zurück zum Zitat Heinzl H (2000) Using SAS to calculate the Kent and O’Quigley measure of dependence for Cox proportional hazards regression model. Comput Methods Programs Biomed 63:71–76PubMedCrossRef Heinzl H (2000) Using SAS to calculate the Kent and O’Quigley measure of dependence for Cox proportional hazards regression model. Comput Methods Programs Biomed 63:71–76PubMedCrossRef
20.
Zurück zum Zitat Kent J, Quigley J (1988) Measures of dependence for censored survival data. Biometrika 75:525–534CrossRef Kent J, Quigley J (1988) Measures of dependence for censored survival data. Biometrika 75:525–534CrossRef
21.
Zurück zum Zitat Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349PubMedCrossRef Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349PubMedCrossRef
22.
Zurück zum Zitat Radovic S et al (2007) Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. Bosn J Basic Med Sci 7:205–211PubMed Radovic S et al (2007) Non-small cell lung carcinoma: cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors. Bosn J Basic Med Sci 7:205–211PubMed
23.
Zurück zum Zitat Saad AG et al (2008) Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 113:2129–2138PubMedCentralPubMedCrossRef Saad AG et al (2008) Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 113:2129–2138PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Giatromanolaki A et al (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80–88PubMedCrossRef Giatromanolaki A et al (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80–88PubMedCrossRef
25.
Zurück zum Zitat Medetoglu B et al (2010) Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg 140:996–1000PubMedCrossRef Medetoglu B et al (2010) Tumor angiogenesis in predicting the survival of patients with stage I lung cancer. J Thorac Cardiovasc Surg 140:996–1000PubMedCrossRef
26.
Zurück zum Zitat Kreuter M et al (2009) Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 33:1383–1388PubMedCrossRef Kreuter M et al (2009) Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 33:1383–1388PubMedCrossRef
27.
Zurück zum Zitat Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107–112PubMedCrossRef Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107–112PubMedCrossRef
28.
Zurück zum Zitat Pezzella F et al (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417–1423PubMedCentralPubMed Pezzella F et al (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417–1423PubMedCentralPubMed
29.
Zurück zum Zitat Kienast Y et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16:116–122PubMedCrossRef Kienast Y et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16:116–122PubMedCrossRef
30.
Zurück zum Zitat Mangili F et al (1998) Cell loss and proliferation in non-small cell lung carcinoma: correlation with histological subtype. Eur J Histochem 42:287–295PubMed Mangili F et al (1998) Cell loss and proliferation in non-small cell lung carcinoma: correlation with histological subtype. Eur J Histochem 42:287–295PubMed
31.
Zurück zum Zitat Guo S et al (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77:389–393PubMedCrossRef Guo S et al (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77:389–393PubMedCrossRef
32.
Zurück zum Zitat Collaud S et al (2012) Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer 78:234–238PubMedCrossRef Collaud S et al (2012) Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung Cancer 78:234–238PubMedCrossRef
33.
Zurück zum Zitat De Ruysscher D et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547–1555PubMedCrossRef De Ruysscher D et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547–1555PubMedCrossRef
34.
Zurück zum Zitat Hu C et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106:1998–2004PubMedCrossRef Hu C et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106:1998–2004PubMedCrossRef
35.
Zurück zum Zitat Nieder C et al (2007) The role of postoperative radiotherapy after resection of a single brain metastasis. Combined analysis of 643 patients. Strahlenther Onkol 183:576–580PubMedCrossRef Nieder C et al (2007) The role of postoperative radiotherapy after resection of a single brain metastasis. Combined analysis of 643 patients. Strahlenther Onkol 183:576–580PubMedCrossRef
36.
Zurück zum Zitat Nieder C et al (1998) Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174:275–278PubMedCrossRef Nieder C et al (1998) Patterns of relapse and late toxicity after resection and whole-brain radiotherapy for solitary brain metastases. Strahlenther Onkol 174:275–278PubMedCrossRef
37.
Zurück zum Zitat Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141PubMedCentralPubMedCrossRef Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Monaco EA 3rd et al (2013) Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119:226–232CrossRef Monaco EA 3rd et al (2013) Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119:226–232CrossRef
39.
Zurück zum Zitat Soffietti R et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31:65–72PubMedCrossRef Soffietti R et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31:65–72PubMedCrossRef
40.
Zurück zum Zitat Rades D, Schild SE (2012) Do patients with a limited number of brain metastases need whole-brain radiotherapy in addition to radiosurgery? Strahlenther Onkol 188:702–706PubMedCrossRef Rades D, Schild SE (2012) Do patients with a limited number of brain metastases need whole-brain radiotherapy in addition to radiosurgery? Strahlenther Onkol 188:702–706PubMedCrossRef
41.
Zurück zum Zitat Bachtiary B et al (2003) Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234–2240PubMed Bachtiary B et al (2003) Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234–2240PubMed
42.
Zurück zum Zitat Sperduto CM et al (2008) A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109(Suppl):87–89PubMed Sperduto CM et al (2008) A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 109(Suppl):87–89PubMed
Metadaten
Titel
Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases
verfasst von
A. S. Berghoff
A. Ilhan-Mutlu
A. Wöhrer
M. Hackl
G. Widhalm
J. A. Hainfellner
K. Dieckmann
T. Melchardt
B. Dome
H. Heinzl
P. Birner, MD
M. Preusser
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 7/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0639-8

Weitere Artikel der Ausgabe 7/2014

Strahlentherapie und Onkologie 7/2014 Zur Ausgabe

Mitteilungen der Fachgesellschaften

Mitteilungen der Fachgesellschaften

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.